Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewFITM is a potent and selective negative allosteric modulator of mGlu1 receptors (IC50 = 5.1 nM). Displays >1300-fold selectivity for mGlu1 over other metabotropic glutamate receptors (IC50 values are 7 μM and >10 μM for mGlu5 and mGlu2 or mGlu8, respectively). Antagonizes methamphetamine-induced locomotion in mice.
FITM is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 371.43 |
Formula | C18H18FN5OS |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 932737-65-0 |
PubChem ID | 16660135 |
InChI Key | WIVGIKIKQHUFOD-UHFFFAOYSA-N |
Smiles | CC(C)NC1=CC(=NC=N1)C1=CSC(=N1)N(C)C(=O)C1=CC=C(F)C=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 37.14 | 100 | |
ethanol | 7.43 | 20 |
The following data is based on the product molecular weight 371.43. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.69 mL | 13.46 mL | 26.92 mL |
5 mM | 0.54 mL | 2.69 mL | 5.38 mL |
10 mM | 0.27 mL | 1.35 mL | 2.69 mL |
50 mM | 0.05 mL | 0.27 mL | 0.54 mL |
References are publications that support the biological activity of the product.
Satoh et al (2009) Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist. Bioorg.Med.Chem.Lett. 19 5464 PMID: 19674894
Wu et al (2014) Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science. 344 58 PMID: 24603153
If you know of a relevant reference for FITM, please let us know.
View all Glutamate (Metabotropic) Group I Receptor Modulators
Keywords: FITM, FITM supplier, potent, selective, negative, allosteric, modulator, antagonist, mGlu1, group, I, metabotropic, glutamate, receptor, Glutamate, (Metabotropic), Group, Receptors, 6859, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for FITM. Do you know of a great paper that uses FITM from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review FITM and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.